Contact Us
Clarified Precision Medicine Headquarters
447 Sutter St., Suite 405 PMB13,San Francisco, CA 94108
info@clarifiedmedicine.com435.288.0640
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
At least half of oncologists report a lack of confidence in interpreting 50 to 100-page next-generation sequencing (NGS) tests. Since few oncologists are trained in genomics—which has only become an integral element of the specialty in recent years—providers have largely been unable to translate the results of biomarker testing into optimal practice.
A Diaceutic study of U.S. patients diagnosed with non-small cell lung cancer (NSCLC), the most common form of lung cancer and one that is especially receptive to precision therapies, showed that 64% of patients failed to receive the appropriate treatment for their needs. Patients who have tumors that express these biomarkers but were given conventional treatments experienced worse survival rates than their counterparts who received personalized treatments.
By providing tangible value to both patients and physicians, Clarified Precision Medicine is serving as a positive influence for all stakeholders, driving greater adoption of NGS testing while growing the larger precision-medicine specialty. We further support pharmaceutical companies by providing their partners with high-quality, patient-level data that can help them effectively widen utilization of precision-targeted treatments.